"Future not dependant on Novartis Interim data from the Phase II/III TIME trial in non-small cell lung cancer (NSCLC) supports the continuation of the trial into Phase III as there was a clinically meaningful improvement in PFS in patients with low levels of the triple-positive activated lymphocyte (TrPAL) biomarker. Despite the strength of the data, Novartis might still decide not to exercise its option to in-license TG4010 for strategic reasons; a decision is due by mid-April. This capital raise means that Transgene could move the TIME trial into the Phase III phase without Novartis if necessary while it looks for another partner."
Smart move by Transgene ensuring wither way they can progress forward with TG4010
VHL has sort of done the same thing by acquiring new cancer projects and diversifying themselves away from a sole reliance on CO-X-Gene
As Ive said a few times not sure why this isnt higher given the peer comparisons
VHL Price at posting:
1.6¢ Sentiment: None Disclosure: Held
